메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
이준희 (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.) 유재민 (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.) 안지현 (Department of Surgery Yonsei University College of Medicine Seoul Korea.) 조수연 (Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.) 이세경 (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.) 유종한 (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.) 채병주 (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.) 남석진 (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, K) 한진일 (Gencurix Inc. Seoul Korea.) 이정언 (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, K) 김석원 (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.)
저널정보
한국유방암학회 Journal of Breast Cancer Journal of Breast Cancer Vol.25 No.6
발행연도
2022.12
수록면
473 - 484 (12page)
DOI
10.4048/jbc.2022.25.e49

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: The GenesWell™ breast cancer test (BCT) is a recently developed multigene assay that predicts the risk of distant recurrence in patients with hormone receptor-positive (HR+) and human epidermal growth factor-2 negative (HER2−) early breast cancer (BC). The ability of this assay to predict the response to neoadjuvant chemotherapy (NACT) has not been established to date. Methods: Biopsy specimens from HR+/HER2− BC patients with axillary lymph node (LN) metastasis who underwent NACT were analyzed using the BCT score. The modified BCT score was developed and patients classified into high-and low-response groups. A total of 88 patients were available for the BCT score among the 108 eligible patients. The median follow-up duration was 35.9 (7.8–128.5) months. Results: Among them, 61 (65.1%) had cN1 and 53 (60.2%) had cT1 or cT2 disease. The BCT score was low in 25 (28.4%) patients and high in 63 (71.6%). Among the 50 patients with pathologic complete response or partial response, 41 (82.0%) were in the high BCT score group and 9 (18.0%) were in the low BCT score group. Among the 38 patients with stable or progressive disease, 22 (57.9%) were in the high BCT score group and 16 (42.1%) were in the low BCT score group (p = 0.025). Ki-67 before NACT was a significant factor for predicting tumor response (p = 0.006; 3.81 [1.50–10.16]). The BCT score showed a significant response to NACT (p = 0.016; 4.18 [1.34–14.28]). Distant metastasis-free survival was significantly different between the high- and low-response groups (p = 0.004). Conclusion: We demonstrated that the BCT score predicts NACT responsiveness in HR+/HER2− BC with LN metastasis and might help determine whether NACT should be performed. Further studies are required to validate these results.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0